Company intelligence / Profile preview

Tezcat Biosciences

New Haven, Connecticut, United States

Ownership: Private
Employees: ~5
Development stage: Other

Overview

Tezcat Biosciences is developing a novel class of protein-drug conjugates that exploit the macropinocytosis pathway to deliver cytotoxic payloads specifically to cancer cells with mutant RAS. Their technology is designed to be both indication and payload agnostic. The company’s lead program targets adult patients with mutant RAS-driven solid tumors and myeloma. Supported by academic collaborations and government awards, their platform is scalable for multiple indications.

Therapeutic areas: Oncology
Modalities: Protein-drug conjugateBiologicVaccine
Industry: Biotech

Drug pipeline

3 assets

Tezcat Imaging Program

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Academic collaborations

Beyond the preview

Go deeper on Tezcat Biosciences.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Tezcat Biosciences.

Explore the full profile